Archival patient tumor tissue from the RANGE trial was analyzed for PD-L1 IHC (22C3), according to the PD-L1 IHC 22C3 pharmDx Interpretation Manual for UC20 (see Methods), to determine PD-L1 expression present in tumor cells (TC), immune cells (IC), and the CPS, which accounts for expression in both cell types. This evidence concerns the gene CD274 and neoplasm.